Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Similar
Filing Names

Inserm institut National De La Sante Et De La Recherche Medicale
Inserm institut National De La Sant xc9 Et De La Recherche M xc9 dicale
Inserm
Inserm institut National De La Sant xe9 Et De La Recherche M xe9 dicale
Inserm Institut National De La Sante Et De La Recherche Medicale
Inserm institut National De La Sante Et De La Rec Herche Medicale
Inserm institut National De La Sante Et De La Rec
Inserm institut National De La Sante De La Recherche Medicale
Inserm institut National De La Sant xc9 Et La Recherche M xc9 dicale
Inserm institut National De La Sante Et De La Recherche Medicate
Inserm institut National De La Sante Et De La Rec Herche
Inserm institute National De La Sante Et De La Recherche Medicale
Inserm Institut De La Recherche M xc9 dicale
Inserm Institut National De La Sant xc9 Et De La Recherche M xc9 dicale
Inserm institut National De La Sante Et La Recherche Medicale
Inserm institut National De La Sant xc9 Etde La Recherche M xc9 dicale
Inserm institut National De Al Sante Et De Al Rec
Inserm institut National De La Recherche Medicale
Inserm institut National De La Sant Et De La Recherche Medicale
Inserm institut National De Al Santa Et De La Recherche Medicale
Inserm institut Natioal De La Recherche Medicale
Inserm institut De La Sante Et De La Recherche Medicale
Inserm institut Naational De La Sant xe9 Et De La Recherche M xe9 dicale
Inserm institut National De La Sant e Et De La Recherche Medicale
Inserm institut National De La Sant xc9 De La Recherche M xc9 dicale

Inserm patents


Recent patent applications related to Inserm. Inserm is listed as an Agent/Assignee. Note: Inserm may have other listings under different names/spellings. We're not affiliated with Inserm, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "I" | Inserm-related inventors


Method for treating cancer

The present invention relates to a method for preventing or treating cancer in an individual comprising administering the individual with a prophylactically or therapeutically effective quantity of a gingival fibroblast-derived product.... Inserm

Lighting apparatus with optimum stimulation of non-visual functions

The lighting equipment comprises a lighting device with a plurality of light sources for delivering white light having a tunable light spectrum, and a monitoring and control device that controls the light sources in a modulation cycle for modulating the light spectrum, which cycle comprises a first period where the... Inserm

Method for preparing a vaccine antigen, resulting vaccine antigen and uses

The present invention relates to a method for preparing a vaccine antigen, which includes a step of fragmenting a biological membrane associated with said vaccine antigen by treating said biological membrane with at least one calixarene of formula (II): wherein: X is a —(CH2)-CO2Y group and Y is an alkaline... Inserm

Selective nox-1 inhibitor peptides and uses thereof

The present invention relates to novel peptides, compositions and methods for the prevention and/or treatment of pathological conditions and diseases associated with NADPH oxidase 1 (Nox1) activity, and/or increased reactive oxygen species (ROS) production. The novel peptides are thus particularly useful for treating and/or preventing cancer, atherosclerosis, angiogenesis, and aging.... Inserm

Auto-inducible expression system

A method for the expression of a protein of interest by a bacterium, notable in that it comprises the culturing of a bacterium temporarily or continuously expressing an Hsp protein, in that said bacterium also comprises a nucleic acid sequence, encoding a protein of interest, under the control of a... Inserm

Immunological treatment of cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy

The present invention relates to an anti-Notch 3 antibody therapy useful for treatment of patients with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. In particular, the invention relates to an anti-Notch3 antibody or a fragment thereof having a 2 fold, 4 fold or 10 fold higher affinity to... Inserm

Inhibitors of fusion between viral and cell membranes as well as compositions and methods of using them

The present application relates to an inhibitor of fusion between a viral membrane from an enveloped virus and a cell membrane, where the viral membrane comprises a fusion mediating protein including a C-terminal peptide. The inhibitor comprises the C-terminal peptide of the fusion mediating protein from an enveloped virus and... Inserm

Method of screening of compounds using membrane stim1

Use of a fraction of STIM1 protein localized to the plasma membrane of the cells in a method for screening candidate molecules for treating chronic lymphatic leukaemia and/or systemic lupus erythematosus is described. Also described are substances interacting with the fraction of the STIM1 protein localized to the plasma membrane... Inserm

Chimeric polypeptide comprising the fragment b of shiga toxin and peptides of therapeutic interest

wherein B represents the B fragment of Shiga toxin or a functional equivalent thereof, and X represents one or more polypeptides of therapeutic significance. Compositions for therapeutic use comprising the polypeptide B-X are also included.... Inserm

Methods and kits for classifying diffuse large b-cell lymphomas (dlbcls) into gcb-dlbcls or into abc-dlbcls

The present invention relates to a method for classifying a diffuse large B-cell lymphoma (DLBCL) of a subject into a GCB-DLBCL or into a ABC-DLBCL comprising the step of determining the expression level of 10 genes in a tumor tissue sample obtained from the subject by performing a Reverse Transcriptase... Inserm

New producing outer membrane vesicles

The present invention relates to ex vivo method for producing outer membrane vesicles (OMVs) by expression or overexpression of the hemolysin F gene (hlyF) in gram-negative bacterium.... Inserm

Treatment of a disease associated with retinal degenerative disorder

Treatment of a disease associated with retinal degenerative disorder. The present invention relates to human Transferrin or an active fragment thereof for use in the treatment of a disease associated with retinal degenerative disorder.... Inserm

Flt3 receptor antagonists

The invention pertains to novel FLT3 receptor antagonists of general formula (1). The compounds are useful for the treatment or the prevention of pain disorders, cancer and autoimmune diseases.... Inserm

Combined use of a trka inhibitor and an epha2 inhibitor for using in the treatment of solid cancers, and the prognosis of survival of a patient who has a solid cancer

The invention relates to an EphA2 inhibitor for the use thereof in the treatment of solid cancer treated with a TrkA inhibitor, and a TrkA inhibitor for the use thereof in the treatment of solid cancer treated with an EpbA2 inhibitor. The invention also relates to a method for the... Inserm

Polynucleotides encoding mhc class i-restricted htert epitopes, analogues thereof or polyepitopes

This invention relates to the field of anticancer therapy, and to the identification of immunogenic peptides derived from the human telomerase reverse transcriptase (hTERT). The present invention relates to polynucleotides encoding hTERT epitopes restricted to MHC class I molecule, analogues thereof and polyepitopes containing such epitopes and/or analogues. Are also... Inserm

Compositions and methods for the treatment of nucleotide repeat expansion disorders

The present invention relates to compositions and methods for the treatment of nucleotide repeat expansion disorders such as myotonic dystrophy.... Inserm

Methods and pharmaceutical compositions for the treatment of bone metastases

The present disclosure relates to methods and pharmaceutical compositions for the treatment of bone metastases. In particular, the present disclosure relates to an agent selected from the group consisting of an anti-ROB04 antibody, an anti-ROB04 aptamer, a ROB04 decoy polypeptide, an inhibitor of ROB04 expression for use in a method... Inserm

Non-invasive imaging of tumor pd-l1 expression

The present invention relates to a method for detecting a PD-L1-positive tumor in a patient by imaging using a radiolabelled anti-PD-L1 antibody.... Inserm

Methods and pharmaceutical compositions for the treatment of pancreatic cancer

The present invention relates to methods and pharmaceutical compositions for the treatment of pancreatic cancers. In particular, the present invention relates to an OX1R agonist for use in the treatment of pancreatic cancer in a subject in need thereof.... Inserm

Anti-pd-l1 immunotoxin for use in therapy

The present disclosure relates to a combination of an anti-PD-L1 (Programmed Cell Death 1 Ligand 1) with an ‘immunotoxin’ for use in a method for treating a tumor in a patient. Experimental results are provided for a combination of an anti POL 1 antibody with the radioisotope Indium 111.... Inserm

Anti-claudin 1 monoclonal antibodies for the prevention and treatment of hepatocellular carcinoma

Use of anti-Claudin 1 monoclonal antibodies and pharmaceutical compositions thereof, for the prevention and/or treatment of hepatocellular carcinoma in patients suffering from liver disease, in particular liver disease that is not associated with HCV infection or in patients who have been cured from HCV infection. Methods of preventing and/or treating... Inserm

Hepcidin antagonists for use in the treatment of inflammation

The present invention relates to a hepcidin antagonist for use in the treatment of inflammatory diseases.... Inserm

Method for processing an asynchronous signal

Disclosed is a method for processing an asynchronous signal produced by a light sensor, the sensor having a pixel matrix disposed opposite a scene, the method including: receiving from the light sensor the asynchronous signal including, for each pixel of the matrix, successive events from the pixel; analysing the asynchronous... Inserm

Method for the 3d reconstruction of a scene

The present invention concerns a method for the 3D reconstruction of a scene comprising the matching (610) of a first event from among the first asynchronous successive events of a first sensor with a second event from among the second asynchronous successive events of a second sensor depending on a... Inserm

Synthetic single domain antibody

The invention relates to the identification of a highly stable single domain antibody scaffold (hs2d Ab) and its use in generating synthetic single domain antibody library (hs2d Ab-L1). The invention also relates to antigen-binding proteins comprising said stable single domain antibody scaffold and their uses, in particular as therapeutics.... Inserm

Polypeptides for engineering integrase chimeric proteins and their use in gene therapy

The present invention relates to polypeptide for engineering integrase chimeric proteins and their use in gene therapy. In particular, the present invention relates to a polypeptide which comprises the amino acid sequence ranging from the amino acid residue at position 617 to the amino acid residue at position 622 in... Inserm

Anaplerotic therapy of huntington disease and other polyglutamine diseases

The present invention relates to a method for treating and/or preventing Huntington disease and other polyglutamine disease, comprising the step of administering an effective amount of a precursor of propionyl-CoA to an individual in need thereof.... Inserm

Anti-rho gtpase conformational single domain antibodies and uses thereof

The present invention relates to active form specific anti-Rho GTPase conformational single domain antibodies and their uses in particular in the therapeutic and diagnostic fields. In particular, the present invention relates to a single domain antibody wherein the amino acid sequences of CDR1-IMGT, CDR2-IMGT and CDR3-IMGT have at least 90%... Inserm

Methods for on demand pre-exposure prophylactic treatment of hiv infection

The present invention relates to methods for on demand pre-exposure prophylactic treatment of HIV infection. In particular, the present invention relates to a method for on demand pre-exposure prophylactic treatment of a subject at substantial risk for HIV infection comprising administering orally the subject with a combination of a therapeutically... Inserm

Methods for the diagnosis of pancreatic cancer

The present invention relates to the diagnosis of pancreatic cancer, in particular to a salivary mi RNA for use in the diagnosis of pancreatic cancer.... Inserm

Human monoclonal antibodies against orexin receptor type 1

The present disclosure relates to human monoclonal antibodies against orexin receptor type 1 (OX1R, hyprocretin 1) and uses thereof for the treatment of cancer. The antibodies are characterized by their CDRs: NYYMN, YISGSSRNIYYADFVKG, SNYDGMDV (Heavy chain) and AGTSSDVGGSNYVS, PGKAP, SSYTYYSTRV (Light Chain)) or the CDRS having at least 50% or... Inserm

Device for measuring the brain activity signals of an individual

Disclosed is a device suitable for measuring the brain activity signals of an individual, the device being intended to be placed on the head of the individual and having a structure intended to carry sensors, the structure allowing the position of the sensors to be adjusted. The structure of the... Inserm

Hpv particles and uses thereof

The invention relates to modified HPV particles that can be used therapeutically. Modified HPV particles may be used to deliver therapeutic agents, including siRNA molecules. Modified HPV particles may be used for the treatment of diseases or conditions of mucosal tissue, including HPV (human papilloma virus) infection and HPV-related tumors.... Inserm

Transgenic rpe cells overexpressing otx2 for the treatment of retinal degeneration

The present invention relates to methods and composition for use in the treatment of retinal degeneration, in particular retinal degeneration due to retinal pigment epithelium dysfunction.... Inserm

11/30/17 / #20170342415

Methods for the prevention and the treatment of extracapillary glomerulonephritis

The present invention relates to the prevention and the treatment of extracapillary glomerulonephritis such as rapidly progressive glomerulonephritis and collapsing glomerulonephritis.... Inserm

11/16/17 / #20170326024

Vibrotactile stimulation device

A vibrotactile stimulation device intended to be applied against a body environment (MC) to be stimulated and comprising a vibrating effector suitable for applying, to said environment, pulses of mechanical vibrational energy, and a controller controlling the effector according to stimulation rules. The device is remarkable in that it further... Inserm

11/16/17 / #20170326025

Vibrotactile stimulation device

A vibrotactile stimulation device intended to be applied against a body medium (MC) to be stimulated, produced in the form of a functional unit, comprising a vibrating effector suitable for applying, to said medium, pulses of mechanical vibrational energy, and a controller for controlling the effector according to stimulation rules.... Inserm

11/16/17 / #20170327572

Treatment of acute exacerbations of chronic obstructive pulmonary disease by antagonism of the il-20r

The present invention relates to methods and pharmaceutical compositions for the treatment of acute exacerbation of chronic obstructive pulmonary disease. In particular, the present invention relates to a method of treating acute exacerbation of chronic obstructive pulmonary disease in a subject in need thereof comprising administering the subject with a... Inserm

11/09/17 / #20170319661

Methods and pharmaceutical compositions using orexins (oxa, oxb) for the treatment of prostate cancers

The present disclosure relates to methods and pharmaceutical compositions for the treatment of prostate cancers. In particular, the present invention relates to an OX1R agonist for use in the treatment of prostate cancer in a subject in need thereof.... Inserm

11/09/17 / #20170319738

Cyclic antimicrobial pseudopeptides and uses thereof

The present invention provides cyclic antimicrobial pseudopeptides that are useful in a variety of applications. Also provided are pharmaceutical compositions, products and kits comprising such cyclic antimicrobial peptides and methods of using these antimicrobial peptides for modifying infectivity, killing microorganisms or inhibiting microbial growth or function and for preventing and/or... Inserm

11/09/17 / #20170321283

Methods of diagnosing cancer and of predicting response of cancer to dendrogenin a treatment

The present invention relates to methods for the diagnosis and the treatment of cancer, in particular breast cancer. In particular, the present invention relates to a method of diagnosing cancer in a subject comprising the steps of i) determining the expression level of hGSTA1 in a tumor sample obtained from... Inserm

11/02/17 / #20170313751

Methods and pharmaceutical composition for the preservation of vascular endothelial cell barrier integrity

The invention relates to an ANGPTL4 polypeptide for use in the preservation of vascular endothelial cell barrier integrity and reduction in no-reflow phenomenon with myocardial infarction.... Inserm

11/02/17 / #20170313758

Polypeptides for the treatment of angiogenesis or lymphangiogenesis-related diseases

The present invention relates to polypeptides for the treatment of angiogenesis or lymphangiogenesis-related diseases. In particular, the present invention relates to a a polypeptide which comprises or consists of a sequence of at least 5 consecutive amino acids in SEQ ID NO: 1 and which comprises at least one amino... Inserm

10/19/17 / #20170298408

Automated analyzing and interpreting an antimicrobial susceptibility

The present invention relates to a method of interpreting different antibiogram images in which it is possible to recognize a phenotype of bacterial resistance relative to antibiotics by comparing photographs using a photographic image bank of the reference antibiogram without any need to interpret them using the EUCAST or CA-SFM... Inserm

09/28/17 / #20170273992

Pharmaceutical compositions for preventing glucocorticoid-induced corneal or skin thinning

The present invention relates to method and pharmaceutical compositions for preventing glucocorticoid-induced corneal or skin thinning. In particular, the present invention relates to a mineralocorticoid receptor antagonist for topical use in a method for preventing or reducing glucocorticoid-induced corneal or skin thinning in a subject in need thereof. The invention... Inserm

09/28/17 / #20170275372

Antibodies directed against icos for treating graft-versus-host disease

The invention relates to a specific antibody directed against, for use for treating graft versus host disease.... Inserm

09/21/17 / #20170268009

Methods and pharmaceutical compositions for treatment of cystic fibrosis

The present invention relates to a method and compositions for the treatment of cystic fibrosis.... Inserm

09/14/17 / #20170258871

Combined use of a trka inhibitor and an epha2 inhibitor for using in the treatment of solid cancers, and the prognosis of survival of a patient who has a solid cancer

The invention relates to an EphA2 inhibitor for the use thereof in the treatment of solid cancer treated with a TrkA inhibitor, and a TrkA inhibitor for the use thereof in the treatment of solid cancer treated with an EpbA2 inhibitor. The invention also relates to a method for the... Inserm

09/14/17 / #20170260588

Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors

The invention relates to methods for detecting inactivation of the DNA Homologous Recombination pathway in a patient, and in particular for detecting BRCA1 inactivation.... Inserm

08/31/17 / #20170247335

Fluorinated pyridazin-3-ones for the use thereof in the treatment of lung diseases

The present invention concerns compounds belonging to the family of fluorinated pyridazin-3-ones, for the use thereof in the treatment of broncho-pulmonary conditions. In compounds having a formula, or a pharmaceutically acceptable salt of the compound, the formula includes R1 representing H, an alkyl, an aryl or a heteroaryl; either E2... Inserm

08/31/17 / #20170247705

Methods and pharmaceutical compositions for the treatment of erythropoietic protoporphyria

The present invention relates to methods and pharmaceutical compositions for the treatment of Erythropoietic Protoporphyria. In particular, the present invention relates to a method for increasing the amount of functional FECH in a erythroid cell carrying the hypomorphic allele IVS3 48C/T (rs2272783) in trans to a deleterious mutation in the... Inserm

08/17/17 / #20170233478

Antibodies directed against icos and uses thereof

The present invention provides antibodies directed against ICOS or a derivative thereof which neutralize ICOS engagement on Treg by inhibiting the fixation between ICOS and ICOS-L and abrogate proliferation of Treg induced by plasmacytoid dendritic cells. The present invention further provides antibodies directed against ICOS or a derivative thereof which... Inserm

08/10/17 / #20170226148

3-(4'-substituted)-benzyl-ether derivatives of pregnenolone

The invention relates to a compound of Formula (I), or a pharmaceutically acceptable salt thereof: wherein R1 is C1-8 alkyl, C1-8 alkoxy, CN, NO2, amino, COOH, COOCH3, OH, N3, or halogen and R2 is H, OH, C1-8 alkyl, C1-8 alkoxy, C2-C6 alkenyl, halogen, Bn-O—, Bn- optionally substituted, or Ph- optionally... Inserm

08/03/17 / #20170218057

Anti-neurotensin long fragment antibodies and uses thereof

The present invention relates to a neutralising antibody which is capable of binding to neurotensin with high affinity. The antibody of the present invention neutralises the activity of neurotensin, in particular the oncogenic activities of neurotensin. In particular, the present invention relates to a neutralising antibody which binds to the... Inserm

08/03/17 / #20170218082

Human soluble cd146, preparation and uses thereof

The present invention relates to compositions and methods for modulating angiogenesis in vivo, ex vivo or in vitro. More particularly, the invention relates to a soluble CD146 protein usable in the context of human therapy, as well as to corresponding antibodies. Particular forms of CD146, herein described, may be used... Inserm

07/27/17 / #20170209488

Methods for treating neuromuscular junction-related diseases

The present invention relates to methods for treating neuromuscular junction-related diseases. In particular, the present invention relates to a method of treating a neuromuscular junction-related disease in a subject in need thereof comprising ad ministering the subject with a therapeutically effective amount of at least one inhibitor of glycogen synthase... Inserm

07/27/17 / #20170210710

2-oxo-3,4-dihydropyridine-5-carboxylates and their use

The present invention is directed to novel compounds of Formula (I), pharmaceutically acceptable salts or solvates thereof, and their use.... Inserm

07/20/17 / #20170202925

Pharmaceutical compositions comprising agonists of orexin-1 receptor ox1r for the treatment of inflammatory bowel diseases

The present invention relates to methods and pharmaceutical compositions for the treatment of inflammatory bowel diseases. The presents methods relates to a method of treating an inflammatory bowel disease in a subject in need thereof comprising administering the subject with a therapeutically effective amount of at least one OX1R agonist.... Inserm

07/06/17 / #20170191084

Method for producing methane by means of aerobic co-culture of anaerobic micro-organisms

The present invention relates to the biological production of methane (Biogas) by co-culture in an aerobic atmosphere of a methanogenic bacterium and of an anaerobic bacterium capable of producing hydrogen, in a culture medium comprising or being supplemented with carbohydrate compound(s), notably starch and/or sugars, and supplemented with antioxidant compound(s).... Inserm

06/29/17 / #20170183662

Methods and compositions for treating neuropathic pain

The present invention relates to an inhibitor of FXYD2 gene expression for use in a method for treating neuropathic pain in a patient in need thereof. The invention also relates to a pharmaceutical composition comprising an inhibitor of FXYD2 gene expression, wherein said pharmaceutical composition is formulated for a direct... Inserm

06/29/17 / #20170183620

Use of uric acid for culturing bacteria sensitive to oxygen tension

The present invention relates to a method for cultivating in vitro in an acellular culture medium, bacteria for which the growth is sensitive to oxygen content, said bacterium being selected from anaerobic bacteria and intracellular micro-aerophilic bacteria, characterized in that uric acid is added into said acellular culture medium, and... Inserm

06/29/17 / #20170183662

Methods and compositions for treating neuropathic pain

The present invention relates to an inhibitor of FXYD2 gene expression for use in a method for treating neuropathic pain in a patient in need thereof. The invention also relates to a pharmaceutical composition comprising an inhibitor of FXYD2 gene expression, wherein said pharmaceutical composition is formulated for a direct... Inserm

06/29/17 / #20170184566

Methods for determining whether a patient will achieve a response after radiation therapy

Disclosed are methods for determining whether a patient will achieve a response after radiation therapy, in particular a method for determining whether a patient suffering from a cancer will achieve a response after radiation therapy including the steps of i) determining the level of ceramide in a first blood sample... Inserm

06/22/17 / #20170175107

Methods for selecting binders by phage display and masked selection

The present invention relates to methods for selecting binders by phage display and masked selection. More particularly, the present invention relates to a method for selecting a plurality of binders specific for at least one relevant target comprising screening a phage binder library of binders against the relevant target in... Inserm

Patent Packs
06/22/17 / #20170176417

Method and pharmaceutical composition for use in the treatment of neurodegenerative disorders

The invention relates to compounds which activate the BASIGIN signalling pathway, preferably agonists of BASIGIN, for the treatment of neurodegenerative disorders.... Inserm

06/22/17 / #20170176446

Methods for determining the oncogenic condition of cell, uses thereof, and methods for treating cancer

The invention relates to methods for detecting the oncogenic condition of cells, including step where the amount of the OCDO compound in said cells is measured, and to the uses thereof. The invention further relates to OCDO inhibitors for use in methods for treating cancer.... Inserm

06/15/17 / #20170166892

Methods and pharmaceutical compositions for the treatment of cardiovascular fibrosis

The present invention relates to methods and pharmaceutical compositions for the treatment of cardiovascular fibrosis. In particular, the present invention relates to an inhibitor of Neutrophil Gelatinase-Associated Lipocalin (NGAL) activity or expression for use in a method for treating or preventing cardiovascular fibrosis in a subject in need thereof.... Inserm

05/25/17 / #20170145423

Use of mcoln-1 modulators to regulate cell migration

The present invention relates to the use of modulators of Mcoln-1 for modulating the cells migration, in particular the migration of dendritic cells and tumor cells, especially for antitumoral vaccination, autoimmune diseases treatment, and metastasis prevention.... Inserm

05/18/17 / #20170137419

Derivatives of 2h-pyrazolo[4,3-c]quinolin-3(5h)-one and use thereof

The invention relates to compounds of formula (I) or the pharmaceutically acceptable solvates thereof, as well as to the use thereof as a drug.... Inserm

05/11/17 / #20170128433

Inhibitors of the pp1/gadd34 complex for the treatment of a condition requiring an immunosuppressive activity

The present invention relates to the general field of treatment and prevention of diseases involving an inflammatory condition, namely sepsis or infectious or viral diseases as well as diseases requiring for the treatment of immunosuppressive activity namely autoimmune diseases and graft rejection. In particular, the invention relates to an inhibitor... Inserm

05/11/17 / #20170131285

Methods and compositions for diagnosing, monitoring and treating cancer

The invention relates to methods for diagnosing cancer and determining the responsiveness to chemotherapyin a subject based on the detection of HSP70-expressing exosomes in a bodily fluid sample obtained from said subject. The invention also relates to methods for treating cancer and in particular methods for restoring or enhancing the... Inserm

04/27/17 / #20170114113

Polypeptides as apelin inhibitors and uses thereof

The present invention relates to polypeptides and their uses as apelin inhibitors. More particularly, the present invention relates to a polypeptide comprising the sequence as set forth in SEQ ID NO:1 wherein at least one arginine residue at position 18, 19, 22 or 23 has been substituted or deleted.... Inserm

03/09/17 / #20170067053

Methods for preventing and treating chronic kidney disease (ckd)

The present invention relates to methods for preventing and treating chronic kidney disease (CKD).... Inserm

03/09/17 / #20170067105

Methods for selecting competent oocytes and competent embryos with high potential for pregnancy outcome

The present invention relates to a method for selecting a competent oocyte or a competent embryo by determining the expression level of specific microRNA species in a body fluid or in cumulus cells.... Inserm

02/23/17 / #20170049854

Methods and pharmaceutical compositions for the cardioprotection

The present invention relates to methods and pharmaceutical compositions for cardioprotection of subjects who experienced a myocardial infarction. In particular, the present invention relates to a ligand of the sonic hedgehog signaling pathway for use in the cardioprotection of a subject who experienced a myocardial infarction.... Inserm

02/23/17 / #20170049862

Methods and pharmaceutical compositions for treating vaso-occlusive crisis

The present invention relates to methods and pharmaceutical compositions for treating vaso-occlusive crises. In particular, the present invention relates to a method of treating a vaso-occlusive crisis in a subject in need thereof comprising administering to the subject a therapeutically effective amount of agent capable of degrading, destabilizing or depleting... Inserm

02/23/17 / #20170051062

Methods and pharmaceutical compositions for the treatment of diseases mediated by the nrp-1/obr complex signaling pathway

The present invention relates to methods and pharmaceutical compositions for the treatment of diseases mediated by the NRP-1/OBR complex signaling pathway. In particular, the present invention relates to a method for treating a disease selected from the group consisting of cancers, obesity and obesity related diseases, anorexia, autoimmune diseases and... Inserm

02/23/17 / #20170052202

Methods for diagnosing and treating iron dysregulation

The present invention relates to methods for diagnosing and treating iron overload and iron deficiency.... Inserm

02/16/17 / #20170044234

Polypeptides and uses thereof for reducing cd95-mediated cell motility

The present invention relates to polypeptides and uses thereof for reducing CD95-meditated cell motility. In particular, the present invention relates to a polypeptide having an amino acid sequence having at least 70% of identity with the amino acid sequence ranging from the amino-acid residue at position 175 to the amino-acid... Inserm

Patent Packs
02/16/17 / #20170044533

Methods for the treatment of leber congenital amaurosis

The present invention relates to a method for treating a Leber congenital amaurosis in a patient harbouring the mutation c.2991+1655 A>G in the CEP290 gene, comprising the step of administering to said patient at least one antisense oligonucleotide complementary to nucleic acid sequence that is necessary for preventing splicing of... Inserm

01/26/17 / #20170020847

Methods and pharmaceutical compositions for the treatment of beta-thalassemias

The present invention relates to methods and pharmaceutical compositions for the treatment of beta-thalassemias. In particular, the present invention relates to an XPO1 inhibitor for use in a method for treating beta-thalassemia in a subject in need thereof.... Inserm

01/19/17 / #20170014426

Ulipristal acetate for prevention and treatment of breast tumors

The invention relates to the use of ulipristal acetate, or any of its metabolites, in preventing or treating a breast tumor in a patient, preferably a patient that carries a mutation in BRCA1 gene.... Inserm

12/07/17 / #20170348542

System for treatment by photodynamic therapy and preparation of such system

System for treatment by photodynamic therapy comprising: —an illuminating device (10) including a light emitting surface for illuminating an internal surface to be treated with a light adapted to activate a photosensitizer compound, the light emitting surface emitting light with a distribution of light power comprising fractions of light power... Inserm

05/11/17 / #20170130267

Methods for predicting acute rejection in heart recipients

The present invention relates to method for predicting acute rejection in heart recipients. In particular, the present invention relates to a method for predicting acute rejection in a heart recipient comprising the steps consisting of i) determining the expression level (ELi) of at least one miRNAi selected from the group... Inserm

01/18/18 / #20180016579

Methods for the treatment of leber congenital amaurosis

The present invention relates to a method for treating a Leber congenital amaurosis in a patient harbouring the mutation c.2991+1655 A>G in the CEP290 gene, comprising the step of administering to said patient at least one antisense oligonucleotide complementary to nucleic acid sequence that is necessary for preventing splicing of... Inserm

03/16/17 / #20170074876

Diagnosis lupus

The present invention relates to an in vitro method for diagnosing lupus in a subject, said method comprising the step of detecting in a biological sample obtained from the subject the autoantibody recognizing the protein biomarker THEX1. More, the invention relates to kits and array useful for carrying out diagnosis... Inserm

05/04/17 / #20170119804

Composition comprising a combination of dna methylation inhibitor and a vitamin d receptor agonist for the treatment of drug resistant cancer or for the prevention of tumor relapse

The present invention concerns a combination of (i) a DNA methylation inhibitor, and (ii) a Vitamin D receptor agonist, for simultaneous or sequential use in the treatment of a drug resistant cancer and/or in prevention of tumor relapse in a patient suffering from cancer. The present invention also relates to... Inserm

03/02/17 / #20170056397

Selective histamine h4 receptor antagonists for the treatment of vestibular disorders

The invention relates to Histamine H4 receptor antagonists or inhibitors of Histamine H4 receptor gene expression for the treatment and/or the prevention of vestibular disorders.... Inserm

02/01/18 / #20180030136

Icos binding proteins

The present invention relates to an ICOS binding protein or antigen binding portion thereof that is an agonist to human ICOS and does not induce complement, ADCC, or CDC when placed in contact with a T cell in vivo and methods of treating cancer, infectious disease and/or sepsis with said... Inserm

02/01/18 / #20180030415

Use of a laminin for differentiating pluripotent cells into hepatocyte lineage cells

The invention relates to the use of a laminin (LN) as a matrix for hepatic differentiation. The invention also relates to a method for inducing hepatic differentiation comprising the steps of: (i) providing a population of human pluripotent cells, (ii) culturing the population on a support coated with a laminin... Inserm

11/30/17 / #20170342494

Methods for predicting graft alterations

The invention relates to a method for predicting graft alterations in a transplanted patient, comprising a step of determining the expression levels of bactericidal/permeability-increasing protein (BPI), chemokine (C motif) ligand 1 (XCL1) and thioredoxin domain containing 3 (TXNDC3) genes in a biological sample obtained from said transplanted patient.... Inserm

10/26/17 / #20170304402

Use of low dose il-2 for treating autoimmune – related or inflammatory disorders

The present invention relates to novel therapies for treating autoimmune and inflammatory diseases. More specifically, the present invention relates to a use of low dose interleukin-2 for the treatment of type I diabetes and other autoimmune and/or inflammatory diseases.... Inserm

09/07/17 / #20170253664
06/01/17 / #20170151235

Sulphate salts of n-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1h-benzo[d]imidazol-2-amine, preparation thereof and use of the same

The present invention relates to sulphate salts of N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine and pharmaceutically acceptable solvates thereof, preparation thereof, pharmaceutical compositions containing them and use of the same in the treatment and/or prevention of neurodegenerative diseases.... Inserm

03/23/17 / #20170080123

Method for preparing porous scaffold for tissue engineering, cell culture and cell delivery

The present invention relates to a method for preparing a porous scaffold for tissue engineering. It is another object of the present invention to provide a porous scaffold obtainable by the method as above described, and its use for tissue engineering, cell culture and cell delivery. The method of the... Inserm

03/16/17 / #20170072032

Prenatal therapy to induce immune tolerance

Constructs and methods for inducing immune tolerance during gestation, e.g. in utero, are provided. The constructs comprise a moiety that targets and binds to the neonatal Fc receptor (FcRn) and a moiety comprising an antigen of interest for which immune tolerance is desired. Administration of the constructs to a fetus... Inserm

02/09/17 / #20170037148

Antibodies for the prevention or the treatment of bleeding episodes

The invention relates to an isolated monoclonal antibody that specifically binds to the D4 domain of VWF, competes for binding to VWF D4 domain with ADAMTS13 and partially inhibits ADAMTS 13 -mediated degradation of VWF. More particularly, the invention relates to an isolated monoclonal antibody comprising a heavy chain wherein... Inserm

01/26/17 / #20170021015

Novel immunoadjuvant flagellin-based compounds and use thereof

The present invention relates to novel peptide compounds derived from flagellin originating from Salmonelle enterica that exhibit an in vivo immune adjuvant activity.... Inserm

07/06/17 / #20170190787

Anti- egfr conformational single domain antibodies and uses thereof

The present invention relates to anti-Epidermal Growth Factor Receptor (EGFR) conformational single domain antibodies and uses thereof in particular in the therapeutic and diagnostic field.... Inserm

02/08/18 / #20180036427

Methods and pharmaceutical compositions for the treatment of hiv infection

The present invention relates to methods and pharmaceutical compositions for the treatment of HIV infection. In particular, the present invention relates to a method of treating HIV infection in a subject in need thereof comprising administering the subject with a therapeutically effective amount of the oligonucleotide comprising the sequence as... Inserm








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Inserm in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Inserm with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###